Hansa Biopharma enters EUR 115 million Idefirix licensing deal with SERB Pharmaceuticals

Reuters2026/07/22 05:04

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Hansa Biopharma signed a EUR 115 million licensing deal with SERB Pharmaceuticals for Idefirix in solid-organ transplant across Europe, the UK, Switzerland, Norway, Iceland, Liechtenstein, MENA.
Received an initial EUR 110 million payment in early July.
Will receive a further EUR 5 million once the EMA accepts the application to convert Idefirix to full marketing authorization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansa Biopharma AB published the original content used to generate this news brief via Cision (Ref. ID: 202607220100BITN____UKPR__SV_20260721-BIT-0802-0) on July 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Hansa Biopharma enters EUR 115 million Idefirix licensing deal with SERB Pharmaceuticals

You may also like

Crypto prices